FR2773994B1 - Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central - Google Patents

Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central

Info

Publication number
FR2773994B1
FR2773994B1 FR9800728A FR9800728A FR2773994B1 FR 2773994 B1 FR2773994 B1 FR 2773994B1 FR 9800728 A FR9800728 A FR 9800728A FR 9800728 A FR9800728 A FR 9800728A FR 2773994 B1 FR2773994 B1 FR 2773994B1
Authority
FR
France
Prior art keywords
biodavailability
tropism
proteases
delivery
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9800728A
Other languages
English (en)
Other versions
FR2773994A1 (fr
Inventor
Pierre Vierling
Roger Guedj
Di Giorgio Andrey Farese
Jacques Greiner
Marielle Rouquayrol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Nice Sophia Antipolis UNSA
Original Assignee
Universite de Nice Sophia Antipolis UNSA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nice Sophia Antipolis UNSA filed Critical Universite de Nice Sophia Antipolis UNSA
Priority to FR9800728A priority Critical patent/FR2773994B1/fr
Publication of FR2773994A1 publication Critical patent/FR2773994A1/fr
Application granted granted Critical
Publication of FR2773994B1 publication Critical patent/FR2773994B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
FR9800728A 1998-01-23 1998-01-23 Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central Expired - Fee Related FR2773994B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9800728A FR2773994B1 (fr) 1998-01-23 1998-01-23 Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9800728A FR2773994B1 (fr) 1998-01-23 1998-01-23 Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central

Publications (2)

Publication Number Publication Date
FR2773994A1 FR2773994A1 (fr) 1999-07-30
FR2773994B1 true FR2773994B1 (fr) 2002-10-11

Family

ID=9522099

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9800728A Expired - Fee Related FR2773994B1 (fr) 1998-01-23 1998-01-23 Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central

Country Status (1)

Country Link
FR (1) FR2773994B1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101631568B (zh) * 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US7157561B2 (en) 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US20030100088A1 (en) * 2001-07-13 2003-05-29 Sigler Gerald F. Protease inhibitor conjugates and antibodies useful in immunoassay
US7202092B2 (en) 2001-07-13 2007-04-10 Roche Diagnostics Operations, Inc. Indinavir derivatives useful in immunoassay
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
US6821744B2 (en) 2002-10-29 2004-11-23 Roche Diagnostics Operations, Inc. Method, assay, and kit for quantifying HIV protease inhibitors
RS54237B9 (sr) 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
PL3150586T3 (pl) 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
AU2008275744A1 (en) 2007-07-06 2009-01-15 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
JP5629585B2 (ja) 2008-01-04 2014-11-19 ギリアード サイエンシーズ， インコーポレイテッド シトクロムｐ４５０のインヒビター
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US20110195940A1 (en) 2008-09-17 2011-08-11 Nektar Therapeutics Protease Inhibitors Having Enhanced Features
EP2344201A1 (fr) * 2008-09-17 2011-07-20 Nektar Therapeutics Conjugués inhibiteurs de protéase-oligomère
WO2010144869A2 (fr) * 2009-06-12 2010-12-16 Nektar Therapeutics Inhibiteurs de protéase
CN108586574B (zh) * 2018-04-26 2019-11-12 国家海洋局第三海洋研究所 氨基葡萄糖肽类化合物及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
DE69729646T2 (de) * 1996-05-09 2005-07-07 Infectio Recherce Inc., Ste-Foy Formulierung zur verwendung in der vorbeugung von pathogen-induzierten erkrankungen, einschliesslich hiv und hsv

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101631568B (zh) * 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物

Also Published As

Publication number Publication date
FR2773994A1 (fr) 1999-07-30

Similar Documents

Publication Publication Date Title
FR2773994B1 (fr) Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
MA26420A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
DZ2523A1 (fr) Formulations pharmaceutiques contenant du voriconazole et procédé pour leur préparation.
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA23899A1 (fr) Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
WO2001041761A3 (fr) Compositions de valdecoxib
CA2293470A1 (fr) Derives de benzimidazole
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr) Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
DZ2414A1 (fr) 2-amino-6-(2-substitué-4-phenoxy)substituté-pyridines procédé pour leur préparation et compositions pharmaceutiques les contenant.
WO2001011086A3 (fr) Nouvelles techniques de diagnostic de l'angiogenese, compositions et techniques de criblage pour modulateurs d'angiogenese
DE19580261D2 (de) Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktion
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
MA26417A1 (fr) Azetidines, procede pour leur preparation, et compositions pharmaceutiques les contenant
MA26777A1 (fr) Inhibiteurs d'aminotransferase dependante d'aminoacide en chaine ramifiee et leur usage dans le traitement de la retinopathie diabetique.
MA26609A1 (fr) Derives de retiferol, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26441A1 (fr) Derives de pyrrolidinyl- et pyrrolinyl- ethylamine, procede pour leur preparation et compositions pharmaceutiques les contenant

Legal Events

Date Code Title Description
ST Notification of lapse